-
Medical journals
- Career
ROCKET AF study – Is the end of warfarin coming?
Authors: J. Špinar 1; J. Vítovec 2
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno-Bohunice 1; Interní kardiangiologická klinika LF MU a FN u sv. Anny v Brně 2
Published in: Kardiol Rev Int Med 2011, 13(2): 106-108
Overview
Anti-coagulation therapy is the basis of the treatment of atrial fibrillations in all their variations. This therapy consists in the administration of vitamin K antagonists, in our conditions warfarin. This requires strict INR monitoring, where INR < 2.0 means an inefficient treatment while INR > 3.0 means a high risk of haemorrhage. The American Heart Association considers studies involving drugs that are to replace warfarin in patients with atrial fibrillations to be one of the 10 most important discoveries of 2010. They are the RE-LY, ROCKET AF and AVEROES studies. The ROCKET AF study has demonstrated in 14,246 patients a trend towards a reduction in CMP and systemic embolisation in the treatment with rivaroxaban compared to warfarin, without increasing the haemorrhage risk. The number of incidents per 100 patient-years was 1.71 with rivaroxaban therapy and 2.16 with warfarin therapy (p < 0.001 for non-inferiority). In February 2011, the ARISTOTLE study with apixaban was completed and the ENGAGE study with edoxaban is in progress.
Keywords:
atrial fibrillation – warfarin – rivaroxaban
Sources
1. Camm AJ, Kirchhof P, Lip GYH et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–2429.
2. Ezekowitz MD, Conolly S, Pareth A et al. Rationale and design of RE-LY randomised evaluation of long term antikoagulant therapy, warfarin compared with dabigatran. Am Heart J 2009; 157: 805–810.
3. Conolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 : 1139–1151.
4. Špinar J, Vítovec J. Komu zvoní hrana? Kardiol Rev 2009; 11 : 197–199.
Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology
Article was published inCardiology Review
2011 Issue 2-
All articles in this issue
- Prediction and prevention of cardiovascular risk of obesity, personalized obesity treatment
- Prediction and prevention of atherosclerosis and personalized treatment of dyslipidemia
- Prediction and prevention of diabetes mellitus type 2
- Individualized therapy of arterial hypertension
- Tabacco smoking and personalized approach in prevention and treatment
- ROCKET AF study – Is the end of warfarin coming?
- Patients with high cardiovascular risk in outpatient care in Slovakia: lessons from the NEMESYS and STAIRS studies
- Thrombosis of mitral annulus as an early complication following mechanical replacement of mitral and aortal valves: case report
- A case of atypical heart failure
- Cardiology Review
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue- Prediction and prevention of atherosclerosis and personalized treatment of dyslipidemia
- Individualized therapy of arterial hypertension
- Prediction and prevention of diabetes mellitus type 2
- A case of atypical heart failure
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career